Shannon 2006.

Methods	computer generated rondom numbers in group of 15; misoprostol tablets were providede in sealed, opaque envelopes after administration of mifepristone.
Participants	971 women, mean age 28 years, < 56 days of gestation; mean gestational age of 44 days. Exclusion criteria: haemoglobin < 9.5 g/dl, active hepatic or renal disease, type I diabetes mellitus, adrenal insufficiency, glaucoma, sickle cell anaemia, coagulopathy, uncontrolled seizure disorder, severe cardiovascular disease, allergy or intolerance to study medication, use of chronic oral steroid medications or anticoagulants Study conducted in 2001 at University of British Columbia; University of Sherbrooke; Laval University; University of Toronto;  Canada
Interventions	Mifepristone 200mg followed 24‐28 hours later by: group 1: misoprostol 400mcg oral group 2: misoprostol 600mcg oral group 3: 800mcg misoprostol vaginal. Misoprostol self administered at home.  Participants were advised to take a second dose of misoprostol in case bleeding was less than normal menstruation. Ultrasound after 7 days  ‐ if ongoing pregnancy: misoprostol 800mcg vaginally
Outcomes	complete abortion, acceptability, side effects
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment (selection bias)	Low risk	A ‐adequate